Pegaptanib Therapy in Non-Infectious Uveitic Cystoid Macular Edema
Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
According to a recent estimate more than 280,000 people in the United States are affected by
uveitis each year. This report, also estimated that uveitis is the reason for 30,000 new
cases of blindness/year and up to 10 percent of all cases of blindness. The purpose of this
trial is to determine the effectiveness of VEGF blockade with intravitreal pegaptanib in
patients with uveitic CME.